Bao Wen, Kong Rui, Wang Nan, Han Wei, Lu Jie
Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
PPAR Res. 2021 Apr 20;2021:6629455. doi: 10.1155/2021/6629455. eCollection 2021.
At present, there are more and more patients with acute hypertriglyceridemia pancreatitis in clinical practice. Common treatment measures include fasting and water withdrawal, fluid resuscitation, and somatostatin. In recent years, studies have pointed out that the PPARa agonist fenofibrate may help improve the condition of such patients. Therefore, through clinical research and analysis, we reported for the first time that fenofibrate combined with octreotide acetate has a more excellent effect in the treatment of patients with acute hypertriglyceridemia pancreatitis, and from the perspective of signal pathways, we revealed that the combination of the two drugs has an effect on NF-B P65. The synergistic inhibitory effect proves that the combined treatment is beneficial to control inflammation, protect liver function, and improve the prognosis of patients. It is worthy of clinical promotion.
目前，临床上急性高甘油三酯血症性胰腺炎患者越来越多。常见的治疗措施包括禁食禁水、液体复苏以及使用生长抑素。近年来，研究指出过氧化物酶体增殖物激活受体α（PPARα）激动剂非诺贝特可能有助于改善此类患者的病情。因此，通过临床研究与分析，我们首次报道非诺贝特联合醋酸奥曲肽在治疗急性高甘油三酯血症性胰腺炎患者方面具有更优异的效果，并且从信号通路角度揭示了两种药物联合对核因子κB（NF-κB）P65具有协同抑制作用，证明联合治疗有利于控制炎症、保护肝功能并改善患者预后，值得临床推广。
